IN THE CLAIMS:

Claims 1-19 (Cancelled).

Claim 20. (New) A method of obtaining a regulatory T cell, comprising contacting a naive CD4⁺ T cell with a stimulatory signal and an appropriate amount of a combination of Vitamin D3 and Dexamethasone, wherein the regulatory T cell produces essentially only IL-10.

Claim 21. (New) The method of Claim 20, wherein the stimulatory signal comprises anti-CD3 and anti-CD28.

Claim 22. (New) The method of Claim 20, wherein the regulatory T cell produces little or no:

- a) IL-4;
- b) IL-5; or
- c) IFN-γ.

Claim 23. (New) The method of Claim 20, wherein:

- a) the regulatory T cell suppresses response to a defined antigen; or
- b) the naive CD4⁺ T cell is also contacted with an antagonist of:
 - i) IL-4;
 - ii) IFN-γ; and/or
 - iii) IL-12.

Claim 24. (New) The method of Claim 20, wherein the contacting is in vitro.

Claim 25. (New) The method of Claim 24, wherein the contacting occurs two times.

Claim 26. (New) The method of Claim 24, wherein the amount of Vitamin D3 is about 4 times higher than the amount of Dexamethasone.

Docket: DX01177B Page 8 of 11

- Claim 27. (New) The method of Claim 24, wherein the amount of:
 - a) Vitamin D3 is at least 1 x 10⁻⁸ M; and/or
 - b) Dexamethasone is at least 2.5 x 10⁻⁹ M.
- Claim 28. (New) The method of Claim 27, wherein the amount of:
 - a) Vitamin D3 is at least 3 x 10⁻⁸ M; and/or
 - b) Dexamethasone is at least 7.5 x 10⁻⁹ M.
- Claim 28. (New) The method of Claim 23; wherein:
 - a) the response is a pathology inducing response; or
 - b) the contacting occurs in the presence of at least two of the antagonists.
- Claim 29. (New) The method of Claim 20, wherein the regulatory T cells produce:
 - a) at least 100 ng of IL-10 per 10⁶ cells; and
 - b) less than 1 ng of IL-4 per 10⁶ cells.
- Claim 30. (New) The method of Claim 29, wherein the regulatory T cells produce:
 - a) less than 30 pg IL-5 per 10⁶ cells; and/or
 - b) less than 30 pg IFN-γ per 10⁶ cells.
- Claim 31. (New) The method of Claim 20, further comprising administering the regulatory T cell to an animal with a specific antigen.
- Claim 32. (New) The method of Claim 31, wherein:
 - a) the regulatory T cell and the antigen are administered simultaneously;
- b) the animal exhibits signs or symptoms of an inflammatory or autoimmune pathology; or
- c) the administering results in suppression of an inflammatory or autoimmune pathology.
- Claim 33. (New) A method comprising administering regulatory T cells specific for an exogenous antigen with the antigen to an animal undergoing an inflammatory or autoimmune pathology.

Docket: DX01177B Page 9 of 11

Claim 34. (New) The method of Claim 33, wherein:

- a) the exogenous antigen is ovalbumin; or
- b) the regulatory T cells and antigen are administered simultaneously.

Claim 35. (New) The method of Claim 33, wherein the administering results in suppression of the pathology.

Claim 36 (New). A population of cells made by the method of Claim 20.

Docket: DX01177B Page 10 of 11